Repare Therapeutics (NASDAQ:RPTX) Trading Up 0.6% - Time to Buy?

Key Points

• Repare Therapeutics shares rose 0.6% to $1.56, with a market cap of $66.91 million and significant decreases in trading volume, down 87% from the average.
• Institutional investors have shown increased interest, with JPMorgan Chase & Co. raising its holdings by an extraordinary 2,144,950.0% during the 4th quarter.
• Repare Therapeutics specializes in precision oncology, focusing on therapies related to genomic instability using its proprietary SNIPRx platform.

Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report)'s share price rose 0.6% during trading on Friday . The company traded as high as $1.58 and last traded at $1.56. Approximately 93,584 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 712,733 shares. The stock had previously closed at $1.55.

Repare Therapeutics Stock Performance

The firm has a market cap of $65.62 million, a P/E ratio of -0.51 and a beta of 0.84. The stock has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $1.28.

Institutional Trading of Repare Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in shares of Repare Therapeutics by 204.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company's stock worth $45,000 after purchasing an additional 23,127 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Repare Therapeutics in the fourth quarter worth $104,000. JPMorgan Chase & Co. grew its holdings in shares of Repare Therapeutics by 2,144,950.0% in the fourth quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company's stock worth $112,000 after acquiring an additional 85,798 shares during the period. Stifel Financial Corp grew its holdings in shares of Repare Therapeutics by 73.1% in the fourth quarter. Stifel Financial Corp now owns 89,500 shares of the company's stock worth $117,000 after acquiring an additional 37,800 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Repare Therapeutics by 65.5% in the fourth quarter. Millennium Management LLC now owns 170,959 shares of the company's stock worth $224,000 after acquiring an additional 67,638 shares during the period. Institutional investors own 85.09% of the company's stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.